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Abstract: Vaccines are considered one of the greatest medical achievements in the battle 
against infectious diseases. However, the intractability of various diseases such as hepatitis C, 
HIV/AIDS, malaria, tuberculosis, and cancer poses persistent hurdles given that traditional 
vaccine-development methods have proven to be ineffective; as such, these challenges have 
driven the emergence of novel vaccine design approaches. In this regard, much effort has 
been put into the development of new safe adjuvants and vaccine platforms. Of particular 
interest, the utilization of plant virus-like nanoparticles and recombinant plant viruses has 
gained increasing significance as an effective tool in the development of novel vaccines 
against infectious diseases and cancer. The present review summarizes recent advances in 
the use of plant viruses as nanoparticle-based vaccines and adjuvants and their mechanism 
of action. Harnessing plant-virus immunogenic properties will enable the design of novel, 
safe, and efficacious prophylactic and therapeutic vaccines against disease. 
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1. Introduction 
Although vaccines have allowed great achievements such as a significant reduction in incidence, 
mortality, and morbidity related to infectious diseases, the field of vaccinology has faced several challenges 
in recent years. Indeed, development of new vaccines has proven difficult especially against chronic 
infections or cancer. To overcome these obstacles, large research efforts are being devoted to better 
understand the key elements required to generate protective immunity. For example, while the majority 
of available vaccines mainly induce the generation of antibodies that neutralize targeted pathogens, it is 
now recognized that the cellular immune response is often necessary to protect against many infections. 
A balanced and complete immune response involving both humoral immunity, with high-affinity 
neutralizing antibodies limiting pathogen transmission and cellular immunity, with cytotoxic CD8+  
T cells killing infected cells, is in fact required to control malaria, hepatitis C, and HIV/AIDS, just to list 
a few [1–5], highlighting the need for the development of new vaccine design approaches. Moreover, 
antigens and epitopes from several pathogens targeted by protective immune responses have recently 
been identified [6–9]. This has led to the design of safer and more specific recombinant vaccines, 
although they are often less immunogenic than more traditional vaccines based on live/attenuated 
pathogens. Therefore, the choice of vaccine formulations and the addition of suitable adjuvants will 
likely be required to achieve protective immunity with these novel vaccines. It is generally accepted that 
the best way to generate vaccines capable of generating a broad immune response with high levels of 
antibodies and cytotoxic T lymphocytes is to mimic a pathogenic infection while remaining as safe as 
possible. In this regard, virus-like nanoparticles (VLPs) have been increasingly studied in recent years 
with the aim of developing new effective vaccines. 
2. Virus-Like Nanoparticles 
VLPs mimic viruses by bearing similar protein composition while being non-infectious. In fact, most 
VLPs do not contain any viral genetic material while others contain nucleic acids that do not allow virus 
replication in mammals. For now, there are three vaccines composed of VLPs used in humans: the 
hepatitis B vaccine, the human papilloma vaccine, and the recently approved vaccine against hepatitis E 
in China [10]. These generate robust humoral immune responses but still require the addition of an 
adjuvant to be fully effective. Other VLPs are currently in clinical trials [11–13] and many more are in 
development [14–16]. The increase in VLP use in the development of novel vaccines is related to their 
numerous qualities that meet new medical needs. For example, their highly ordered and repetitive 
structures facilitate recognition by the immune system and induce B-cell activation through B-cell 
receptor (BCR) cross-linking [17]. The size of VLPs is generally between 20 and 300 nm, which is ideal 
to be effectively recognized by dendritic cells (DCs) or other antigen-presenting cells (APC) [18–21]. In 
addition, VLPs frequently display various Pathogen Associated Molecular Patterns (PAMPs) that are 
recognized by Pattern Recognition Receptors (PRRs), leading to the activation of the innate immune 
system and cytokine production such as type I interferon (IFN-I); notably, these cytokines were reported 
to increase the cross-presentation capacity of DCs and are beneficial towards cell-mediated, T-lymphocyte 
immune responses [22–24]. IFN-αβ can also increase the humoral response, induce isotype switching, 
and enhance the generation of T follicular helper cells [25,26]. Furthermore, many studies have shown 
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the capacity of VLPs to induce a cellular immune response, therefore permitting the development of 
prophylactic and therapeutic vaccines targeting CD8+ cytotoxic T lymphocyte (CTL) responses [27–30]. 
This strongly correlates with APC cross-presentation of antigens fused to VLPs to CD8+ T cells through 
a Tap- and proteasome-independent pathway [31–33]. This mechanism has also been shown to generate 
tumor-specific CD8+ T-cell responses that efficiently slow down tumor growth and increase mice survival 
in various models [34–36]. Importantly, non-infectious VLPs are safer than attenuated or inactivated 
viruses and could therefore potentially be administered to immunocompromised individuals. Finally, the 
use of VLPs could be advantageous for developing vaccines against viruses that are impossible or 
difficult to grow in culture such as the human norovirus, for example [37]. Altogether, these properties 
contribute to the effectiveness and usefulness of VLP vaccines. 
3. Recombinant Plant Virus Particles (rPVPs) 
Recombinant plant virus particles are increasingly studied as candidate vaccines. They can be classified 
as a subtype of VLP since they are viral particles that are non-infectious in mammals. However, most 
rPVPs retain their replication potential in plants, posing additional safety and environmental challenges. 
Nonetheless, rPVPs possess all of the advantages of VLPs and thus would allow the development of 
effective vaccines. Many plant viruses such as the tobacco mosaic virus (TMV), cowpea mosaic virus 
(CPMV), potato virus X (PVX), alfalfa mosaic virus (AlMV), and papaya mosaic virus (PapMV) (see 
Table 1 for more information) are currently used for the development of new vaccines. Typically, plant 
viruses are simple, rod shaped, or bearing icosahedral symmetry; they are composed of one or two 
repeated coat protein (CP) subunits and bear an RNA genome. These viruses are relatively easy to 
engineer, produced at low cost, and very stable, enabling storage at room temperature, which is desirable 
for vaccination in developing countries. CP modification of plant viruses allows dense expression of 
fused antigens, thereby contributing to the development of an effective immune response. Finally, while 
other virus platforms, such as adenovirus, suffer from platform-specific antibody development [38,39], 
rPVPs seem to maintain their immunogenic properties in the presence of specific antibodies [40,41].  
In the following paragraphs, we will discuss the different methods of production of rPVPs for vaccination, 
the diverse approaches for antigen expression on their surface, and achievements made with rPVPs. 
Table 1. Recombinant plant virus particles used in vaccine development. 
Virus Shape Parameters Tested Element of Response References 
CPMV Icosahedral 
Humoral response 
Binding or neutralizing antibodies [42–54] 
Protection against challenge [42,43,45,47] 
Cellular response IFN-γ production [50,51] 
Immunomodulation APC activation [55] 
PVX Rod 
Humoral response 
Binding or neutralizing antibodies [56–60] 
Protection against challenge [60] 
Cellular response 
CD8+ T cells activation [57,61] 
IFN-γ production [57,61] 
Protection against challenge [57,61] 
Immunomodulation 
APC activation [56,60] 
Cytokine production [60] 
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Table 1. Cont. 
Virus Shape Parameters Tested Element of Response References 
TMV Rod 
Humoral response 
Binding or neutralizing antibodies [41,61–63] 
Protection against challenge [41,63–66] 
Cellular response 
CD8+ T cells activation [40,67,68] 
IFN-γ production [67] 
Protection against challenge [67] 
Immunomodulation APC activation [40,67] 
CMV Icosahedral 
Humoral response Binding or neutralizing antibodies [69] 
Cellular response 
CD8+ T cells activation [69] 
IFN-γ production [69,70] 
AlMV Icosahedral 
Humoral response Binding or neutralizing antibodies [71,72] 
Cellular response IFN-γ production [72] 
PapMV Rod 
Humoral response Binding or neutralizing antibodies [73–75] 
Cellular response 
CD8+ T cells activation [33,76,77] 
IFN-γ production [33,74,76,77] 
Protection against challenge [77] 
Immunomodulation 
APC activation [78] 
Cytokine production [78] 
Protection against challenge [78] 
Adjuvant 
APC activation [79,80] 
Cytokine production [79,80] 
Vaccine jointly administered 
PapMV-M2e [73], 
BMDC-OVA [81], 
Outer Membrane 
Protein C [80], TIV [81], 
Protection against challenge [79–81] 
BaMV Rod 
Humoral response 
Binding or neutralizing antibodies [82,83] 
Protection against challenge [82,83] 
Cellular response 
IFN-γ production [82] 
Protection against challenge [82] 
TBSV Icosahedral Humoral response Binding or neutralizing antibodies [84] 
Plum pox 
potyvirus 
Rod Humoral response Binding or neutralizing antibodies [85,86] 
CMV: cucumber mosaic virus; BaMV: bamboo mosaic virus; TBSV: tomato bushy stunt virus. 
3.1. Production Methods 
rPVP production can be achieved by several methods. Production of rPVPs using plants, such as 
Nicotiana benthamiana, Nicotiana tabacum, or cowpea plants, is the most widely used and can be 
divided into two different strategies, both starting with the production of the desired cDNA. The cDNA 
can then be transcribed in vitro and used to inoculate plants depositing the RNA transcript on abraded 
leaves to induce a systemic infection [64]. Another option is to transform Agrobacterium tumefaciens 
with a plasmid containing the cDNA coding for the modified viral genome and then agroinfiltrate plants 
to induce transient expression and generate recombinant viruses [87]. A week or two later, recombinant 
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viruses are then purified by different techniques [62,66,71]. Remarkably, due to the possibility of CMV 
production in edible vegetables, e.g., celery, lettuce, cucumber, tomato, carrot, pepper, and banana [88], 
plant production also advances the use of oral delivery of vaccine via ingestible plants [89,90]. This 
strategy would therefore reduce costs related to virus purification and eliminate the need for sterile 
needles and trained medical staff for vaccine administration. rPVP manufacturing in planta also allows 
for large-scale production devoid of contamination risks from human pathogens. However, a weakness 
of oral administration of rPVPs is related to the difficulty of controlling the amount of antigen taken by 
the patient and the potential development of tolerance to the antigen. In addition, genetic modifications 
that induce foreign antigen expression on plant virus proteins can sometimes affect viral replication,  
thus reducing production efficiency [88]. A new method based on transgenic plant cell suspension 
cultures was recently developed. This process, based on the culture of calli derived from transgenic  
plant lines expressing viral cDNA, allows for continuous production of large amounts of rPVPs with 
high reproducibility [91]. More conventional techniques are also used to produce rPVPs such as  
bacteria [78,92], yeast [93,94], and insect cell cultures [95,96]. Plants, bacteria, and yeast are all simple 
and low cost manufacturing methods. However, bacteria and yeast sometimes produce insoluble proteins, 
thus restricting particle self-assembly [94,97]. The less practical and more costly baculovirus expression 
system seems to avoid these problems [94–96]. When capsid protein production does not induce particle 
formation, it is also possible to perform the assembly process in vitro, with or without the addition of 
nucleic acids [78,97–99]. Although this process is more laborious, it allows for better control of the RNA 
present inside the particle since diverse and uncontrolled sources of RNA can be incorporated in  
self-assembled viral particles in vivo [93,94,96]. In addition, in vitro assembly allows for the packing of 
specific RNA transcripts in recombinant plant virus capsid proteins that will further induce in vivo gene 
expression [100]. Atabekov and colleagues generated spherical nanoparticles using thermal denaturation 
of the TMV CP protein [101]. These particles are devoid of RNA and can bind different proteins or 
peptides, making it a universal and immunogenic particle platform [102]. Therefore, these different 
manufacturing processes generate rPVPs that either contain no RNA, host RNA, viral RNA, or inactive 
or replicative synthetic RNA. Plant virus particles are most probably safe enough for administration in 
humans, but many are still infectious in plants. Therefore, inactivation methods based on chemical 
treatment or UV irradiation, for example, were developed to ensure that rPVPs are innocuous [43,103,104]. 
Finally, methods using eukaryotic cells have the advantage of allowing post-transcriptional modifications 
ensuring that the rPVP is more similar to the parental virus and more stable [93,94]. In summary several 
manufacturing processes have been developed to efficiently produce the desired rPVP, each with their 
advantages and drawbacks. 
3.2. Antigen Expression on rPVPs 
Several processes lead to the expression of foreign antigens on rPVPs. The most commonly used are 
molecular cloning techniques to fuse sequences coding for the antigen directly within the CP gene construct. 
In the case of icosahedral viruses such as CMV, CPMV, and AlMV, localization within sequences 
exposed on the viral surface as well as sites accepting peptide fusions have been well studied [88,105]. 
In general, insertions of 10–50 amino acids are well tolerated and are structured in closed loops exposed 
on the surface of the virus. For example, most successful fusions with CPMV were achieved by inserting 
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epitopes within loops between amino acids 22 and 23 of the S protein [43,46,51]. Nevertheless, others 
have managed to obtain stable particles using N-terminal or C-terminal fusions with AlMV and TBSV, 
respectively, even if the N-terminal region is known to be important for particle formation for some 
icosahedral viruses [71,96]. However, in some cases, only 20%–30% of rPVP CPs express the fused 
antigen [71]. In the case of rod-shaped viruses, N-terminal and C-terminal fusions are the most 
commonly used [56,57,64,74,77]. This allows surface expression without causing destabilization of the 
structure. In addition, specific and well-defined sites in the CP sequence, other than the C- and N-termini, 
were also shown to accept fusion without destabilization while allowing surface expression of fused 
antigens and recognition by the immune system [106–108]. However, the tolerated size of peptides fused 
to rod-shaped viruses is usually more restricted [58,109]. Therefore, in order to fuse bigger peptides or 
complete proteins, fusion processes other than molecular cloning have been developed. One such 
technique consists in biotinylating the CP to attach streptavidin-linked proteins or peptides [60,62]. 
Others also incorporate a reactive lysine in the sequence of the CP to chemically conjugate peptides 
using a heterobifunctional linker [67,68,100] or perform copper catalyzed azide-alkine cycloaddition to 
covalently link antigens to the viral capsid [52,110]. Spontaneous conjugation due to electrostatic and/or 
hydrophobic interactions between foreign antigens and viral CP can also happen and are further 
stabilized by formaldehyde treatment [101,102]. However, antigen insertion may potentially induce viral 
particle destabilization [70,109,111,112]. Apart from the size and the localization of the peptide, its 
charge and isoelectric point can also impact the particles’ capacity to assemble [109,112,113]. In some 
cases, the generation of mixed particles allows for the formation of stable rPVPs [60]. For example, in 
order to avoid interference with particle assembly, the insertion of the foot-and-mouth disease virus 2A 
peptide in the cDNA construct of PVX benefits from a ribosomal skipping process to produce mixed 
particles made of recombinant and wild-type CPs [58,59]. Finally, the localization of conjugated 
antigens may also affect the ability to elicit an immune response against fused antigens by influencing 
the accessibility and conformation of the antigen and thus the immunogenicity of the rPVP [54,110,111]. 
In summary, with new techniques developed and a better comprehension of factors influencing the 
stability and immunogenicity of rPVPs, we are better equipped to generate effective vaccines and it is 
now possible to conjugate very large peptides [59,114] or even complete protein antigens to such 
particles [62]. 
3.3. rPVPs as Vaccines to Induce Humoral Immune Responses 
Most of the currently used vaccines induce a humoral response upon administration, which will then 
protect individuals against infection or the appearance of disease (reviewed in [115]). As it is the case 
for current vaccines, plant viruses used as vaccine platforms are also able to trigger the production of 
antibodies. Not only are these platforms able to induce IgGs, mainly found in serum after sub-cutaneous, 
intra-peritoneal, and to some extent intra-nasal injections, IgAs are also found in mucosa after intra-nasal 
and oral administration [44,50,51,53,56]. Plant viruses used as carriers for foreign epitopes can therefore 
efficiently induce the production of both systemic and mucosal antibodies following administration by 
various routes, which broadens their potential targets since not all pathogens will require the same 
antibody response to be cleared from the host. The structure of epitopes presented on the surface of 
rPVPs will depend on their localization and size. When in an optimal localization, epitopes will adopt a 
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structure similar to their native conformation, allowing antibodies to recognize the virus or bacteria against 
which they were mounted [54,59]. As such, antibodies from HCV-infected patients were able to recognize 
a CMV engineered virus expressing the R9 peptide from HCV [70], even though these patients were 
never exposed to the rPVP. rPVP-based experimental vaccines were also shown to be as effective or 
even more effective at inducing an antibody response compared to commercially available vaccines [83], 
peptides alone [61,62,73–75], or peptides conjugated to keyhole limpet haemocyanin (KLH) [43,51]. 
Moreover, these vaccines are often administered in conjunction with less toxic adjuvants, compared  
to Freund’s Complete Adjuvant (which is not approved for human use), like QS-21 and QuilA  
(saponin-based) or RIBI [47,48,64], or even without the use of any adjuvant [44,56,57]. Plant viruses 
also often require less peptide to induce efficient antibody responses compared to commercially available 
vaccines or peptides conjugated to KLH [41,46]. 
Immunization in different experimental animal models not only generated specific antibodies but also 
protected against challenge with various viruses, bacteria, or tumor cell lines when epitopes were presented 
on CPMV [42,43,45,48,116], PVX [60,61], Bamboo Mosaic Virus (BaMV) [82,83], or TMV [41,63–66]. 
Protection against challenge (sometimes lethal) is thought to be partially achieved by neutralizing 
antibodies, generated following immunization with engineered CPMV [43,47,51,56,85], PVX [56], and 
Plum Pox Potyvirus [85]. This protection can be broadened to various strains and species of the same 
pathogen using conserved epitopes, which are usually weakly immunogenic. When such epitopes are 
presented on the surface of rPVPs, their immunogenicity is increased, allowing for the production of a 
more effective antibody response and therefore a broader protection of the host [41,49,110]. This has 
been demonstrated for peptides 10 and 18 of the outer membrane protein F of Pseudomonas aeruginosa 
presented at the surface of CPMV [45,117], as well as for the R9 peptide of HCV presented on PVX [58]. 
This broad recognition was also observed when mannose was engineered to be displayed on CPMV 
inducing antibodies interacting with various of its analogues and derivatives [52]. 
Part of the mechanism by which plant virus carriers induce the production of antibodies is hypothesized 
to proceed through cross-linking of the BCR [49]. The presentation of many epitopes in close proximity 
might favor such cross-linking, leading to the proliferation of B lymphocytes, presentation of epitopes 
to T cells, and differentiation of B lymphocytes into antibody-producing plasma cells [17]. In agreement 
with this, Nicholas et al. demonstrated that higher antigen expression on the surface of CPMV particles 
provided a better immune response [51]. It also explains why viral platforms seem more efficient at 
inducing antibodies than peptide-KLH conjugates, for example [43,51]. 
3.4. rPVPs as Vaccines to Induce Cellular Immune Responses 
Even though antibodies generated following vaccination are often sufficient to protect against some 
diseases, elicitation of both cellular and humoral adaptive immune responses is sometimes necessary for 
protection (reviewed in [115]). The use of plant viruses as epitope carriers has proven effective in inducing 
cellular immune responses directed towards antigens presented on the particle. We have demonstrated 
that epitopes fused to the PapMV platform were able to induce the activation of CD8+ T cells by a,  
cross-presentation pathway [33,76,77]. Other rPVPs, such as TMV [40,67,68], CMV [69], CPMV [47] 
and PVX [57,61] were also shown to generate and enhance CD8+ T cell-mediated immune responses 
against fused epitopes. The main correlate for induction of effective T-cell responses seems to be production 
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of IFN-γ. IFN-γ production was observed when peripheral blood mononuclear cells (PBMCs) from 
healthy patients or patients infected with HCV were incubated with AlMV expressing a respiratory 
syncytial virus epitope [72] or CMV expressing the R9 epitope from HCV [69,70], both demonstrating 
that human PBMCs can be activated by rPVPs, while the latter also demonstrates that the epitope is 
efficiently processed and presented, leading to the potent activation of CD8+ T cells (i.e., IFN-γ 
production). Cellular immune responses also correlated with protection against challenge with tumor cell 
lines B16-OVA and Eg.7-OVA [67], Lymphocytic Choriomeningitis Virus [77], and Foot and Mouth 
Disease Virus [84]. 
3.5. rPVPs Used as Immunomodulators and Adjuvants 
In order to generate an effective immune response, APCs must be activated and present antigens to 
cells of the adaptive immune system [118]. As previously mentioned, rPVPs possess many suitable 
characteristics for them to be taken up by APCs, processed, and presented to T cells. Indeed, DCs were 
shown to be activated following TMV [40,67], PVX [56,60], CPMV [55], and PapMV [77,79,80] 
immunization. Activated DCs upregulate various co-stimulatory molecules such as CD40, CD86, CD80, 
MHCII, MHCI, and CCR7 [60,79] and also produce pro-inflammatory cytokines such as IL-12, TNF-α, 
IL-6, and IFN-α [60,78–81]. DCs are not the only cell population that was shown to be activated following 
immunization with rPVPs since B lymphocytes, macrophages, and NK cells can also upregulate activation 
markers following rPVP encounter [55,80]. 
Since rPVPs can be efficiently taken up by APCs and induce their activation, they can potentially  
be used as adjuvants to enhance the effectiveness of concomitantly administered vaccines. We have 
indeed demonstrated that PapMV can be used as an adjuvant in combination with various types of 
vaccines. When PapMV was administered jointly with bone marrow-derived DCs presenting OVA, 
cellular immune responses towards OVA were enhanced, leading to better protection against a  
Listeria monocytogenes-OVA challenge in mice [79]. Similar protection was observed when PapMV 
was administered in mice in concert with the seasonal trivalent influenza vaccine (TIV) [81]. When used 
as an adjuvant, PapMV was also shown to enhance the production of antibodies directed against  
TIV [73,80,81]. PapMV has also been shown to be able to prime the immune system and protect mice 
from an influenza infection on its own, without being fused to an epitope or being administered with a 
separate vaccine [78]. Finally, it was shown to induce a broader immune response against TIV antigens, 
providing protection against strains of influenza not contained within the vaccine [81]. To our 
knowledge, PapMV is the first rPVP used as an adjuvant or an immunomodulator specifically to prime 
the immune system. 
The mechanisms by which rPVPs activate APCs are slowly being uncovered. We have identified one 
such mechanism in the PapMV system as being the recognition of nucleic acid found within rPVPs that 
induces APC activation. Single-stranded RNA (ssRNA) within PapMV particles is in fact recognized by 
TLR7 in endosomes of APCs, mainly plasmacytoid DCs, leading to the production of IFN-α [60,79]. 
The lack of activation of murine splenocytes upon administration of PapMV monomers further illustrates 
the importance of ssRNA for its adjuvancy properties [79]. Of note, despite RNA serving as the major 
immunomodulatory molecule following PapMV administration, the use of RNA alone cannot replace 
rPVPs since it would be rapidly degraded following administration due to the abundance of host RNAses 
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found within the blood or other bodily fluids. The viral capsid therefore provides protection from 
degradation to the RNA molecule, allowing it to be efficiently delivered to endosomes. Plant virus 
particles thus carry their adjuvant properties inside a protective capsid [80], explaining their versatility 
both as vaccines and adjuvants. 
4. Conclusions and Perspectives for rPVPs  
Although there is still much research to be done before rPVPs are used as vaccines in humans, great 
achievements have been made in recent years in this field. Several production and antigen expression 
methods have been developed and improved, thus leading to the generation of many promising candidate 
vaccines. Beyond demonstrating that rPVPs are effective platforms to generate both humoral and cellular 
immune responses against fused antigens, we now know that rPVPs are efficiently recognized by the 
immune system of mammals, which efficiently activates the innate immune system. Therefore, rPVPs 
possess attractive intrinsic adjuvant properties that can be used for immunomodulatory purposes. This 
has important implications for future vaccine design and opens the door for new applications. A strong 
testimony to the recent achievements made in using rPVPs as novel vaccines is the recent entry of two 
rPVPs in clinical trials, PapMV as an adjuvant for the influenza vaccine [119] and AlMV as a vaccine 
against malaria [120]. In light of this, it seems very likely that in the near future plant viruses will be 
used in humans to address unmet medical needs as prophylactic and therapeutic vaccines and 
immunomodulators against infection or cancer. 
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